TY - JOUR AU - Chen, W. PY - 2016 DA - 2016// TI - Cancer statistics in China, 2015 JO - CA Cancer J Clin VL - 66 ID - Chen2016 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2018 DA - 2018// TI - Cancer statistics, 2018 JO - CA Cancer J Clin VL - 68 ID - Siegel2018 ER - TY - JOUR AU - Ramalingam, S. S. AU - Owonikoko, T. K. AU - Khuri, F. R. PY - 2011 DA - 2011// TI - Lung cancer: new biological insights and recent therapeutic advances JO - CA Cancer J Clin VL - 61 ID - Ramalingam2011 ER - TY - JOUR AU - Rami-Porta, R. PY - 2017 DA - 2017// TI - Lung cancer - major changes in the American joint committee on Cancer eighth edition cancer staging manual JO - CA Cancer J Clin VL - 67 ID - Rami-Porta2017 ER - TY - JOUR AU - Meza, R. PY - 2015 DA - 2015// TI - Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010 JO - PLoS One VL - 10 ID - Meza2015 ER - TY - JOUR AU - Arriagada, R. PY - 2010 DA - 2010// TI - Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data JO - Lancet VL - 375 ID - Arriagada2010 ER - TY - JOUR AU - Cersosimo, R. J. PY - 2002 DA - 2002// TI - Lung cancer: a review JO - Am J Health Syst Pharm VL - 59 ID - Cersosimo2002 ER - TY - JOUR AU - Gao, H. PY - 2015 DA - 2015// TI - High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response JO - Nat Med VL - 21 ID - Gao2015 ER - TY - JOUR AU - Hirsch, F. R. PY - 2016 DA - 2016// TI - New and emerging targeted treatments in advanced non-small-cell lung cancer JO - Lancet VL - 388 ID - Hirsch2016 ER - TY - STD TI - Minna, JD and J. Dowell. Erlotinib hydrochloride. Nat Rev Drug Discov. 2005;Suppl: S14–5. ID - ref10 ER - TY - JOUR AU - Shepherd, F. A. PY - 2005 DA - 2005// TI - Erlotinib in previously treated non-small-cell lung cancer JO - N Engl J Med VL - 353 ID - Shepherd2005 ER - TY - STD TI - Yang Z, et al. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: a meta-analysis. Int J Cancer. 2017;140(12):2805–19. ID - ref12 ER - TY - JOUR AU - Pojo, M. PY - 2015 DA - 2015// TI - A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide JO - Oncotarget VL - 6 ID - Pojo2015 ER - TY - JOUR AU - Cardona, A. F. PY - 2017 DA - 2017// TI - Acquired resistance to Erlotinib in EGFR mutation-positive lung adenocarcinoma among Hispanics (CLICaP) JO - Target Oncol VL - 12 ID - Cardona2017 ER - TY - JOUR AU - Kosaka, T. PY - 2006 DA - 2006// TI - Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib JO - Clin Cancer Res VL - 12 ID - Kosaka2006 ER - TY - JOUR AU - Cevenini, A. AU - Orru, S. PY - 2018 DA - 2018// TI - Molecular Signatures of the Insulin-like Growth Factor 1-mediated Epithelial-Mesenchymal Transition in Breast, Lung and Gastric Cancers JO - Int J Mol Sci VL - 19 ID - Cevenini2018 ER - TY - JOUR AU - Jakobsen, K. R. PY - 2016 DA - 2016// TI - The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer JO - Transl Lung Cancer Res VL - 5 ID - Jakobsen2016 ER - TY - JOUR AU - Lee, Y. PY - 2016 DA - 2016// TI - Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells JO - Mol Carcinog VL - 55 ID - Lee2016 ER - TY - JOUR AU - Nurwidya, F. PY - 2014 DA - 2014// TI - Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer JO - Biochem Biophys Res Commun VL - 455 ID - Nurwidya2014 ER - TY - JOUR AU - Witta, S. E. PY - 2006 DA - 2006// TI - Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines JO - Cancer Res VL - 66 ID - Witta2006 ER - TY - JOUR AU - Kobayashi, S. PY - 2005 DA - 2005// TI - EGFR mutation and resistance of non-small-cell lung cancer to gefitinib JO - N Engl J Med VL - 352 ID - Kobayashi2005 ER - TY - JOUR AU - Goldstein, D. M. AU - Gray, N. S. AU - Zarrinkar, P. P. PY - 2008 DA - 2008// TI - High-throughput kinase profiling as a platform for drug discovery JO - Nat Rev Drug Discov VL - 7 ID - Goldstein2008 ER - TY - JOUR AU - Kulasingam, V. AU - Pavlou, M. P. AU - Diamandis, E. P. PY - 2010 DA - 2010// TI - Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer JO - Nat Rev Cancer VL - 10 ID - Kulasingam2010 ER - TY - JOUR AU - Chen, F. PY - 2015 DA - 2015// TI - Gene expression profile for predicting survival of patients with meningioma JO - Int J Oncol VL - 46 ID - Chen2015 ER - TY - JOUR AU - Kulasingam, V. AU - Diamandis, E. P. PY - 2008 DA - 2008// TI - Strategies for discovering novel cancer biomarkers through utilization of emerging technologies JO - Nat Clin Pract Oncol VL - 5 ID - Kulasingam2008 ER - TY - JOUR AU - Lu, Y. PY - 2006 DA - 2006// TI - A gene expression signature predicts survival of patients with stage I non-small cell lung cancer JO - PLoS Med VL - 3 ID - Lu2006 ER - TY - JOUR AU - Dutkowski, J. PY - 2013 DA - 2013// TI - A gene ontology inferred from molecular networks JO - Nat Biotechnol VL - 31 ID - Dutkowski2013 ER - TY - JOUR AU - Kanehisa, M. PY - 2017 DA - 2017// TI - KEGG: new perspectives on genomes, pathways, diseases and drugs JO - Nucleic Acids Res VL - 45 ID - Kanehisa2017 ER - TY - JOUR AU - Lanczky, A. PY - 2016 DA - 2016// TI - miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients JO - Breast Cancer Res Treat VL - 160 ID - Lanczky2016 ER - TY - JOUR AU - Franz, M. PY - 2018 DA - 2018// TI - GeneMANIA update 2018 JO - Nucleic Acids Res VL - 46 ID - Franz2018 ER - TY - JOUR AU - Pathan, M. PY - 2015 DA - 2015// TI - FunRich: an open access standalone functional enrichment and interaction network analysis tool JO - Proteomics VL - 15 ID - Pathan2015 ER - TY - JOUR AU - Lee, D. H. PY - 2017 DA - 2017// TI - Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures JO - Pharmacol Ther VL - 174 ID - Lee2017 ER - TY - JOUR AU - Gammelgaard, K. R. PY - 2019 DA - 2019// TI - Up-regulated FGFR1 expression as a mediator of intrinsic TKI resistance in EGFR-mutated NSCLC JO - Transl Oncol VL - 12 ID - Gammelgaard2019 ER - TY - JOUR AU - Masuda, C. PY - 2017 DA - 2017// TI - Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model JO - Int J Oncol VL - 51 ID - Masuda2017 ER - TY - JOUR AU - Shintani, T. PY - 2018 DA - 2018// TI - Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer JO - Oncotarget VL - 9 ID - Shintani2018 ER - TY - JOUR AU - Ju, T. PY - 2017 DA - 2017// TI - Overexpression of NAC1 confers drug resistance via HOXA9 in colorectal carcinoma cells JO - Mol Med Rep VL - 16 ID - Ju2017 ER - TY - JOUR AU - Abe, M. PY - 2016 DA - 2016// TI - Internal tandem duplication in FLT3 attenuates proliferation and regulates resistance to the FLT3 inhibitor AC220 by modulating p21Cdkn1a and Pbx1 in hematopoietic cells JO - PLoS One VL - 11 ID - Abe2016 ER - TY - JOUR AU - Jung, J. G. PY - 2016 DA - 2016// TI - Ovarian Cancer Chemoresistance relies on the stem cell reprogramming factor PBX1 JO - Cancer Res VL - 76 ID - Jung2016 ER - TY - JOUR AU - Longley, D. B. AU - Johnston, P. G. PY - 2005 DA - 2005// TI - Molecular mechanisms of drug resistance JO - J Pathol VL - 205 ID - Longley2005 ER - TY - JOUR AU - Misale, S. PY - 2012 DA - 2012// TI - Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer JO - Nature VL - 486 ID - Misale2012 ER - TY - JOUR AU - Paez, J. G. PY - 2004 DA - 2004// TI - EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy JO - Science VL - 304 ID - Paez2004 ER - TY - JOUR AU - Horiike, A. PY - 2014 DA - 2014// TI - Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer JO - Anticancer Res VL - 34 ID - Horiike2014 ER - TY - JOUR AU - Zhu, C. Q. PY - 2008 DA - 2008// TI - Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada clinical trials group study BR.21 JO - J Clin Oncol VL - 26 ID - Zhu2008 ER - TY - JOUR AU - Yeung, K. T. PY - 2017 DA - 2017// TI - Circulating tumor DNA for mutation detection and identification of mechanisms of resistance in non-small cell lung Cancer JO - Mol Diagn Ther VL - 21 ID - Yeung2017 ER - TY - JOUR AU - Vora, S. R. PY - 2014 DA - 2014// TI - CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors JO - Cancer Cell VL - 26 ID - Vora2014 ER - TY - JOUR AU - Kapoor, C. PY - 2016 DA - 2016// TI - Seesaw of matrix metalloproteinases (MMPs) JO - J Cancer Res Ther VL - 12 ID - Kapoor2016 ER - TY - JOUR AU - Conlon, G. A. AU - Murray, G. I. PY - 2019 DA - 2019// TI - Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis JO - J Pathol VL - 247 ID - Conlon2019 ER - TY - JOUR AU - Herzog, C. AU - Haun, R. S. AU - Kaushal, G. P. PY - 2019 DA - 2019// TI - Role of meprin metalloproteinases in cytokine processing and inflammation JO - Cytokine VL - 114 ID - Herzog2019 ER - TY - JOUR AU - Diniz-Fernandes, T. PY - 2018 DA - 2018// TI - Matrix metalloproteinase-1 (MMP-1) and (MMP-8) gene polymorphisms promote increase and remodeling of the collagen III and V in posterior tibial tendinopathy JO - Histol Histopathol VL - 33 ID - Diniz-Fernandes2018 ER - TY - JOUR AU - Mazor, R. PY - 2013 DA - 2013// TI - Matrix metalloproteinase-1-mediated up-regulation of vascular endothelial growth factor-2 in endothelial cells JO - J Biol Chem VL - 288 ID - Mazor2013 ER - TY - JOUR AU - Su, Y. P. PY - 2018 DA - 2018// TI - Leptin induces MMP1/13 and ADAMTS 4 expressions through bone morphogenetic protein-2 autocrine effect in human chondrocytes JO - J Cell Biochem VL - 119 ID - Su2018 ER - TY - JOUR AU - Tratwal, J. PY - 2015 DA - 2015// TI - Influence of vascular endothelial growth factor stimulation and serum deprivation on gene activation patterns of human adipose tissue-derived stromal cells JO - Stem Cell Res Ther VL - 6 ID - Tratwal2015 ER - TY - JOUR AU - Shen, C. J. PY - 2017 DA - 2017// TI - MMP1 expression is activated by slug and enhances multi-drug resistance (MDR) in breast cancer JO - PLoS One VL - 12 ID - Shen2017 ER - TY - JOUR AU - Kim, E. PY - 2018 DA - 2018// TI - Capicua suppresses hepatocellular carcinoma progression by controlling the ETV4-MMP1 axis JO - Hepatology VL - 67 ID - Kim2018 ER - TY - JOUR AU - Pei, D. PY - 2005 DA - 2005// TI - Matrix metalloproteinases target protease-activated receptors on the tumor cell surface JO - Cancer Cell VL - 7 ID - Pei2005 ER - TY - JOUR AU - Lu, R. PY - 2016 DA - 2016// TI - COPS5 amplification and overexpression confers tamoxifen-resistance in ERalpha-positive breast cancer by degradation of NCoR JO - Nat Commun VL - 7 ID - Lu2016 ER - TY - JOUR AU - Miao, X. PY - 2016 DA - 2016// TI - Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) expression in non-Hodgkin's lymphoma JO - Tumour Biol VL - 37 ID - Miao2016 ER - TY - JOUR AU - Wu, X. PY - 2018 DA - 2018// TI - Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: a bioinformatic analysis JO - Gene VL - 643 ID - Wu2018 ER - TY - JOUR AU - Zou, W. PY - 2017 DA - 2017// TI - Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer JO - Exp Biol Med (Maywood) VL - 242 ID - Zou2017 ER - TY - JOUR AU - Levinson, H. PY - 2004 DA - 2004// TI - Alpha V integrin prolongs collagenase production through Jun activation binding protein 1 JO - Ann Plast Surg VL - 53 ID - Levinson2004 ER -